Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Invasive Breast Carcinoma|Stage 0 Breast Cancer AJCC v6 and v7|Stage I Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma
Interventions: PROCEDURE: Biospecimen Collection|OTHER: Laboratory Biomarker Analysis|OTHER: Patient Observation|BIOLOGICAL: Pembrolizumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|RADIATION: Radiation Therapy
Sponsor: National Cancer Institute (NCI)